- Home
- NCI vs PRPO Comparison
NCI vs PRPO Comparison
Compare NCI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- PRPO
- Stock Information
- Founded
- NCI 1992
- PRPO N/A
- Country
- NCI Hong Kong
- PRPO United States
- Employees
- NCI N/A
- PRPO N/A
- Industry
- NCI
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- NCI
- PRPO Industrials
- Exchange
- NCI NYSE
- PRPO Nasdaq
- Market Cap
- NCI 10.1M
- PRPO 8.8M
- IPO Year
- NCI 2024
- PRPO N/A
- Fundamental
- Price
- NCI $0.53
- PRPO $5.13
- Analyst Decision
- NCI
- PRPO
- Analyst Count
- NCI 0
- PRPO 0
- Target Price
- NCI N/A
- PRPO N/A
- AVG Volume (30 Days)
- NCI 93.4K
- PRPO 7.0K
- Earning Date
- NCI 12-19-2024
- PRPO 11-06-2024
- Dividend Yield
- NCI N/A
- PRPO N/A
- EPS Growth
- NCI N/A
- PRPO N/A
- EPS
- NCI 0.08
- PRPO N/A
- Revenue
- NCI $22,481,862.00
- PRPO $17,411,000.00
- Revenue This Year
- NCI N/A
- PRPO $75.18
- Revenue Next Year
- NCI N/A
- PRPO N/A
- P/E Ratio
- NCI $7.39
- PRPO N/A
- Revenue Growth
- NCI N/A
- PRPO 31.31
- 52 Week Low
- NCI $0.35
- PRPO $4.31
- 52 Week High
- NCI $11.39
- PRPO $7.30
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- PRPO 31.74
- Support Level
- NCI N/A
- PRPO $4.98
- Resistance Level
- NCI N/A
- PRPO $6.48
- Average True Range (ATR)
- NCI 0.00
- PRPO 0.27
- MACD
- NCI 0.00
- PRPO -0.07
- Stochastic Oscillator
- NCI 0.00
- PRPO 10.02
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company whose a one-stop apparel solution services provider. It offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European, and North American markets through Neo-Concept HK.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.